Precision Therapeutics, Inc. Uses Automated Method To Extract RNA For Use In The GeneFx® Colon Signature
Published: Dec 16, 2013
PITTSBURGH--(BUSINESS WIRE)--Precision Therapeutics announced today the publication of a feasibility study on the GeneFx® Colon microarray-based signature that supports the utilization of a new, automated method for extracting quality RNA. Previous validation efforts utilized a manual extraction process. This study was conducted in conjunction with Siemens Healthcare Diagnostics, Inc. using their Tissue Preparation Solution which includes an extraction platform and reagents. The abstract, titled, Comparison of Fully Automated and Manual Extraction Methods from Formalin-Fixed, Paraffin-Embedded Tissue for Use in a Prognostic Microarray-Based Genomic Signature, is included in the November issue of the Journal of Molecular Diagnostics.
Help employers find you! Check out all the jobs and post your resume.